IQVIA revolutionizes pharmaceutical processes with AI and Microsoft
This case highlights the collaboration between IQVIA, a healthcare and pharma clinical research company, and Microsoft, focusing on embedding AI technologies, including generative AI, into pharmaceutical workflows. AI solutions were adapted specifically for life sciences, notably transforming workflows by automating mundane tasks, enabling employees to focus on strategic efforts. Crucially, these implementations maintained risk mitigation oversight while addressing biases in clinical trials and enhancing employee productivity. AI's ability to enhance productivity, drive patient outcomes, and uncover biases in trial data has made it a transformative tool in the industry, demonstrating its potential to reshape operations profoundly.
- Organization
- IQVIA
- Industry
- Pharma
- Location
- United States
- Published
- January 2024
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- IQVIA
- Provider
- Microsoft
- Maturity
- Production
- Linked source
- IQVIA
Boosted overall productivity and operational efficiency in pharmaceutical workflows
Primary read
Use case focus
Showing 3 of 3
- 1clinical trial bias detection
- 2employee productivity assistance
- 3safety profiling
- Implemented AI, including generative AI, to automate data mining and other manual workflows.
- Used Microsoft's AI capabilities as a 'copilot' to assist employees in improving productivity.
- Applied AI tools to uncover and mitigate biases during pharmaceutical clinical trials.
- Ensured human oversight in generative AI processes to avoid risks and ensure safety.
- Improved employee satisfaction and retention through strategic task focus.
- Boosted overall productivity and operational efficiency in pharmaceutical workflows.
Architecture
The implementation integrated Microsoft's generative AI capabilities as a copilot into IQVIA's workflows. AI-powered tools automated repetitive tasks and enabled employee focus on strategic roles, with data analysis for clinical trial biases ensuring comprehensive demographic safety profiling.
Sources & evidence1
- Customer explicitly identified
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
The case's original source is still reachable.
- Cited source last checked Jun 12, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Was this useful?
Community
Comments
No published comments yet.
Comments could not be loaded.